HDAC inhibition induces microRNA-182 which targets Rad51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia

by Lai, Tsung-Huei, Ewald, Brett, Zecevic, Alma, Liu, Chaomei, Sulda, Melanie, Papaioannou, Dimitrios, Garzon, Ramiro, Blachly, J.S, Plunkett, William, Sampath, Deepa
Published in Clin Cancer Res (2016)

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)

by Bhatnagar, B, Blachly, JS, Kohlschmidt, J, Eisfeld, A-K, Volinia, S, Nicolet, D, Carroll, AJ, Block, AW, Kolitz, JE, Stone, RM, Mrózek, K, Byrd, JC, Bloomfield, CD
Published in Leukemia (2015)

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

by Woyach, J.A., Ruppert, A.S., Heerema, N.A., Zhao, W., Booth, A.M., Ding, W., Bartlett, N.L., Brander, D.M., Barr, P.M., Rogers, K.A., Parikh, S.A., Coutre, S., Hurria, A., Brown, J.R., Lozanski, G., Blachly, J.S., Ozer, H.G., Major-Elechi, B., Fruth, B., Nattam, S., Larson, R.A., Erba, H., Litzow, M., Owen, C., Kuzma, C., Abramson, J.S., Little, R.F., Smith, S.E., Stone, R.M., Mandrekar, S.J., Byrd, J.C.
Published in N Engl J Med (2018)

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

by Young, E, Noerenberg, D, Mansouri, L, Ljungström, V, Frick, M, Sutton, L-A, Blakemore, SJ, Galan-Sousa, J, Plevova, K, Baliakas, P, Rossi, D, Clifford, R, Roos-Weil, D, Navrkalova, V, Dörken, B, Schmitt, CA, Smedby, KE, Juliusson, G, Giacopelli, B, Blachly, JS, Belessi, C, Panagiotidis, P, Chiorazzi, N, Davi, F, Langerak, AW, Oscier, D, Schuh, A, Gaidano, G, Ghia, P, Xu, W, Fan, L, Bernard, OA, Nguyen-Khac, F, Rassenti, L, Li, J, Kipps, TJ, Stamatopoulos, K, Pospisilova, S, Zenz, T, Oakes, CC, Strefford, JC, Rosenquist, R, Damm, F
Published in Leukemia (2016)